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Abstract 
Acute renal failure (ARF) in critically ill patients is currently very frequent and requires renal replacement therapy (RRT) 
in many patients. During the last 15 years, several studies have considered important issues regarding the use of 
RRT in ARF, like the time to initiate the therapy, the dialysis dose, the types of catheter, the choice of technique, and 
anticoagulation. However, despite an abundant literature, conflicting results do not provide evidence on RRT imple‑
mentation. We present herein recommendations for the use of RRT in adult and pediatric intensive care developed 
with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system by an expert 
group of French Intensive Care Society (SRLF), with the participation of the French Society of Anesthesia and Intensive 
Care (SFAR), the French Group for Pediatric Intensive Care and Emergencies (GFRUP), and the French Dialysis Society 
(SFD). The recommendations cover 4 fields: criteria for RRT initiation, technical aspects (access routes, membranes, 
anticoagulation, reverse osmosis water), practical aspects (choice of the method, peritoneal dialysis, dialysis dose, 
adjustments), and safety (procedures and training, dialysis catheter management, extracorporeal circuit set‑up). These 
recommendations have been designed on a practical point of view to provide guidance for intensivists in their daily 
practice.
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Background
The prevalence of acute renal failure (ARF) in intensive 
care, in an unselected population, is high—about 40 %—
and a renal replacement therapy technique is required in 
just under 20 % of patients presenting ARF [1]. The use of 
consensual definitions (RIFLE, KDIGO) for the diagno-
sis and assessment of the severity of renal failure enables 
comparison of types of practice, such as the use of tech-
niques of renal replacement therapy (RRT) [2]. There are 
large disparities between studies. The FINNAKI group 
reported that prevalence of RRT ranged from 3 to 36 % 
among intensive care units, whereas patient mortality 
did not differ [3]. The absence of consensual criteria for 
use of RRT generates great variability, notably in popu-
lations of septic patients for whom some teams use RRT 
in indications other than acute kidney failure. Numerous 
studies over the last 15 years have considered the time to 
initiation of RRT, dialysis dose, types of catheter, choice 
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of technique, and anticoagulation. The last SRLF recom-
mendations on continuous dialysis (1997) are now old, 
and the 2012 international recommendations on manage-
ment of renal failure (ATS-ERRT-ESICM-SCCM-SRLF) 
only partially consider RRT. It therefore seemed neces-
sary to draw up these recommendations for the practi-
cal aspects of RRT to provide guidance for intensivists 
in their daily practice. Most aspects of RRT in adult or 
pediatric ICU have been considered in these recommen-
dations, but some of them have been unheeded in regard 
to the lack of data in the literature or the prioritization 
decided by the panel expert.
Methodology
These recommendations were drawn up by a panel of 
experts brought together by the SRLF in collabora-
tion with scientific societies in disciplines that contrib-
ute to the management of acute renal failure by RRT: 
French Society of Anesthesia and Intensive Care (SFAR), 
French Group for Pediatric Intensive Care and Emer-
gencies (GFRUP) and the French Dialysis Society (SFD). 
The organizing committee appointed a coordinator who 
selected the SRLF experts. Each scientific society asso-
ciated with these expert recommendations selected its 
experts. The coordinator first defined the questions to 
be covered and proposed experts to be in charge of each 
question. A first meeting was organized to discuss the 
proposed questions and the choice of experts to cover 
them, and to approve everything. Literature analysis and 
formulation of recommendations were then performed 
using the GRADE system (Grade of Recommendation 
Assessment, Development and Evaluation) [4, 5]. A level 
of proof was defined for each bibliographic reference as a 
function of the type of study. This level of proof could be 
reassessed taking into account the methodological qual-
ity of the study. The bibliographic references common 
to each outcome were then pooled. An overall level of 
evidence was determined for each outcome, taking into 
account the level of proof of each bibliographic reference, 
the consistency of the results between the different stud-
ies, the direct or indirect nature of the proof, cost analy-
sis, etc. A “strong” level of proof enabled formulation of a 
“strong” recommendation (should be done, should not be 
done). A “moderate,” “weak,” or “very weak” level of proof 
led to the drawing up of an “optional” recommendation 
(should probably be done, should probably not be done 
…). The proposed recommendations were presented 
and discussed at a second meeting of all the experts. 
The aim was not necessarily to reach a single and con-
vergent opinion of the experts regarding all proposals, 
but to bring out the points of agreement and the points 
of disagreement or of indecision. Each recommendation 
was then evaluated by each expert who rated it according 
to a scale from 1 (complete disagreement) to 9 (complete 
agreement). The collective score was established using a 
methodology derived from the RAND/UCLA appropri-
ateness method [6]: after elimination of the extreme val-
ues (outliers), the median and confidence interval of the 
scores were calculated. The median defined disagreement 
between the experts when it was between 1 and 3, agree-
ment between 7 and 9 and indecision between 4 and 6. 
The disagreement, agreement, or indecision was “strong” 
if the confidence interval was within one of three ranges: 
(1–3), (4–6) or (7–9) and “weak” if the confidence inter-
val straddled two ranges. In the absence of strong agree-
ment, the recommendations were reformulated and again 
scored with a view to achieving a better consensus. Two 
rounds of scoring were therefore performed.
Area 1: Criteria for initiation of RRT in renal failure
1.1 RRT should be initiated without delay in life-
threatening situations (hyperkalemia, metabolic 
acidosis, tumor lysis syndrome, refractory pulmo-
nary edema). (Expert opinion) Strong agreement
1.2 The available data are insufficient to define opti-
mal timing of initiation of RRT outside life-threat-
ening situations. (Expert opinion) Strong agree-
ment
Despite the lack of a specific study, the benefit of RRT 
in life-threatening situations seems reasonable, which 
explains why most experts recommend its use in such 
circumstances [7]. Is it useful to initiate it earlier in acute 
renal failure? Several observational, randomized stud-
ies and meta-analyses have examined the benefit of early 
initiation [8–23], but the findings are discordant. Three 
prospective randomized studies showed no benefit [9], 
a deleterious effect [11] or a net benefit [10]. Three pro-
spective open studies found no benefit of early initiation 
of RRT [12–14]. Several observational retrospective stud-
ies of low methodological quality, mostly without adjust-
ment for confounding factors, suggest a benefit [15–23]. 
A meta-analysis of these data suggests a benefit of early 
initiation of RRT [8]. The low level of proof of most stud-
ies considered, the diversity of definitions of early or late 
initiation, the heterogeneity of the study populations, 
unequal quality of available data, observed bias, includ-
ing a strongly suspected publication bias, and the small 
number of patients in these studies mean that definitive 
conclusions cannot be drawn. The findings of the litera-
ture analysis are insufficient to enable a recommendation 
concerning the optimal timing of RRT initiation, outside 
life-threatening situations.
1.3 In children, fluid and sodium overload probably 
of above 10 %, and very probably of above 20 %, 
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should be considered as one of the criteria for ini-
tiation of renal replacement therapy. (Expert opin-
ion) Poor agreement
Several observational studies have shown that fluid 
overload before initiation of RRT is a mortality risk fac-
tor, including multivariate analysis [24–29]. All stud-
ies indicate that the threshold of 20  % fluid overload is 
associated with a large increase in mortality (odds ratio 
8.3) [28]. Between 10 and 20  %, the increase in mortal-
ity is less clear. Foland et al. showed that a fluid overload 
of more than 10  % is enough to increase mortality, but 
only in the group of children with dysfunction of  ≥  3 
organs [25]. While all these data suggest a strong associa-
tion between mortality and fluid overload, no study has 
compared a strategy of intervention by RRT according to 
different fluid overload thresholds, such that the level of 
proof is low and no causal link can be established.
1.4 “ Early” initiation of RRT means at KDIGO stage 2 
or within 24 h after onset of acute renal failure of 
which reversibility seems unlikely. (Expert opin-
ion) Poor agreement
1.5 “Late” initiation of RRT means over 48  h after 
onset of acute renal failure, KDIGO stage 3, or 
when a life-threatening situation arises because of 
acute renal failure. (Expert opinion) Poor agree-
ment
Although the data are insufficient to recommend early 
initiation of RRT, it seems necessary to pursue research 
in this field [8]. In this regard, the control group should 
mimic usual prescribing habits as best as possible [30–
33]. The early or late nature of the intervention should 
therefore be defined as modifying usual practice. The 
KDIGO classification [2], which is used to assess the 
severity of renal failure, seems to be the most suited to 
defining the intervention groups.
Area 2: Technical aspects
Area 2.1: Access routes
2.1.1 The subclavian route should be avoided. (Expert 
opinion) Strong agreement
On the basis of old data on end-stage renal failure 
patients on dialysis, the CDC (http://www.cdc.gov/dial-
ysis/guidelines) and KDOQI (http://www.kidney.org/
professionals/kdoqi/guidelines_commentaries.cfm) rec-
ommend avoiding the placement of temporary RRT cath-
eters at the subclavian  site because of a risk of stenosis 
of the subclavian and axillary veins, which could com-
promise the function of, or the future use of, a perma-
nent access such as an arteriovenous fistula if acute renal 
failure progresses to end-stage renal disease [34]. Recent 
data show that progression to chronic renal failure after 
acute kidney injury occurs in close to 25 % of cases, when 
combining chronic dialysis and doubling of plasma cre-
atinine [35]. In terms of the incidence rate, this risk is 
assessed as 7.8 events/100 patient-years for the presence 
of an acute kidney injury and 4.9 events/100 patient-
years for the presence of end-stage renal disease [36]. In 
view of these data, it seems right not to use the subcla-
vian route as the vascular access for RRT in renal failure.
2.1.2 The femoral vein and right internal jugular vein 
sites should be considered as equivalent in terms 
of infectious complications. Strong agreement
2.1.3 The internal jugular site should probably be 
used to reduce catheter-related infection risk for 
patients with a body mass index above 28 kg/m2. 
Strong agreement
An infectious complication is a local or general infec-
tion secondary to the presence of microorganisms at 
the internal and/or external surface of the catheter. 
The results of nonrandomized studies on the central 
venous catheter are divergent [37, 38]. The femoral 
route is reputed to be associated with an increased risk 
of colonization and infection compared with the jugular 
route. However, nonrandomized studies did not find an 
increased risk of bacteremia with central venous cath-
eterization comparing femoral versus internal jugular 
vein insertion [39, 40]. Although the epidemiology of 
infections associated with dialysis catheters is similar to 
the epidemiology of infections associated with central 
venous catheters, the extrapolation of these results is dif-
ficult. There is a single randomized study in a small popu-
lation comparing the femoral and internal jugular sites 
for RRT with colonization as the main outcome measure 
[41]. The femoral site did not significantly increase the 
risk of colonization of the first catheter (40.8 versus 35.7 
for 1000 catheter-days for the jugular route; P  =  0.31) 
and the rate of catheter-related bloodstream infection 
was similar (1.5 versus 2.3 for 1000 catheter-days for the 
jugular route; P =  0.42). Only the subgroup of patients 
with a body mass index above 28 kg/m2 had an increased 
infectious risk associated with the femoral site. In the 
same prospective randomized study of RRT, the absence 
of difference in colonization between the jugular and 
femoral sites was confirmed by a cross-over analysis of 
the second catheterization [42].
2.1.4 The femoral and right internal jugular sites should 
be considered as equivalent in terms of the risk of 
catheter dysfunction. Poor agreement
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A single prospective randomized study has com-
pared the internal jugular and femoral sites in terms of 
catheter dysfunction and efficacy of RRT [43]. Catheter 
dysfunction was similar at the internal jugular (11.1  %) 
and femoral (10.3 %) sites. The efficacy of RRT, arbitrar-
ily defined by the urea reduction rate in intermittent 
hemodialysis and by the continuous RRT downtime, was 
comparable for the internal jugular and femoral sites. In 
contrast, compared with the jugular site, the femoral site 
was subject to more dysfunction and blood recircula-
tion when the catheter length was <25 cm or if the blood 
flow was >200 mL/min, as reported in patients treated by 
intermittent hemodialysis [43, 44]. The femoral and jugu-
lar sites can therefore be considered equivalent in terms 
of catheter dysfunction, provided use is made of a cath-
eter appropriate to the femoral route.
2.1.5 The left internal jugular site should probably be 
kept as a third choice. Strong agreement
A single study has directly compared the rate of cath-
eter dysfunction according to right or left internal jugu-
lar placement, with respect to femoral placement [43]. In 
this subgroup analysis, the risk of catheter dysfunction 
was significantly higher for the left internal jugular site 
than for the femoral site or the right internal jugular site.
2.1.6 In children, right internal jugular access should 
probably be preferred to femoral access for chil-
dren weighting less than 20 kg (or if the catheter 
is <10F). Poor agreement
2.1.7 Catheter size should be adapted to the child’s 
morphology and body weight. (Expert opinion) 
Strong agreement
• 3–6 kg → 6.5–7 F
•  6–10 kg → 8 F
•  10–20 kg → 8–10 F
•  20–30 kg → 10 F
•  >30 kg → 11–13 F
In children, the preferred insertion site is the right 
internal jugular vein in terms of the quality of dialysis 
[45] and optimization of hemofilter life [46], in particu-
lar for small-caliber catheters (<10 F) [47]. The choice of 
this route should take into account the usual precautions 
concerning the inherent risk of a “high” placement, nota-
bly in cases of respiratory distress or coagulopathy. The 
femoral site is an acceptable alternative, and is feasible 
whatever the patient’s condition. The caliber of the cathe-
ter should be adapted to the child’s body weight, favoring 
catheters of relatively large caliber [47, 48].
2.1.8 For the femoral site, choose catheters of diam-
eter  >12 F and length ≥24  cm. (Expert opinion) 
Strong agreement
Blood flow through the catheter is one of the major 
determinants of the quality of dialysis [49]. The degree 
of recirculation should also be taken into account, even 
though it is generally low (<10 %) when a double-lumen 
catheter is used for vascular access. This percentage, 
which corresponds to the proportion of recirculated 
blood in the catheter, increases when there is turbulence 
in the vein related to low blood flow, in the case of partial 
thrombosis of the catheter and/or of the vein at catheter 
insertion, and/or if the routes are reversed. To ensure 
good catheter performance and effective dialysis, the dis-
tal end should be positioned in a large-caliber vein with 
a high blood flow, so that the quantity of blood available 
in the vessel is never limiting. In patients with end-stage 
renal failure, temporary dialysis catheters shorter than 
20  cm generate more recirculation than catheters over 
20  cm in length [50]. These results were confirmed in 
intensive care in a post hoc analysis of the Cathedia study 
where femoral catheters below 24  cm in length were 
associated with a decrease in the urea reduction rate 
compared with catheters longer than 24 cm [43].
2.1.9 Ultrasound guidance should be used for catheter 
placement in the internal jugular vein in RRT. 
Strong agreement
Ultrasound guidance, in accordance with current inter-
national recommendations, is considered as the refer-
ence technique for placement of central venous catheters 
in intensive care. By guiding insertion in the vein and 
detecting anatomical variations, ultrasound improves the 
success rate and patient comfort, and reduces the time 
needed for placement, the number of attempts per inser-
tion, the number of complications and cost [51–53]. Few 
studies have specifically considered dialysis catheters in 
intensive care. A 2011 meta-analysis of 7 randomized 
studies (830 catheters in total; 3 studies reported only as 
abstracts) compared the placement of 380 dialysis cath-
eters based solely on anatomical landmarks with ultra-
sound-guided placement of 450 dialysis catheters [54]. 
Most of the catheters (85  %) studied were inserted in 
the internal jugular vein. Ultrasound guidance was asso-
ciated with a reduced risk of catheter placement failure 
compared with placement using anatomical landmarks 
(RR  =  0.12; 95  % CI 0.04–0.37). Likewise, ultrasound 
guidance reduced catheter placement failure at the first 
attempt (RR  =  0.4; 95  % CI 0.29–0.56), the number of 
attempts, the time taken to cannulate the vein, as well as 
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the number of complications such as arterial puncture, 
hematoma, and pneumothorax [55–57].
2.1.10 Ultrasound guidance should probably be used 
for femoral vein catheter placement in RRT. Poor 
agreement
One randomized single-center study specifically com-
pared the placement of dialysis catheters by the femo-
ral route using ultrasound guidance or anatomical 
landmarks [58]. The success rate for placement of 110 
double-lumen dialysis catheters was 98.2  % with ultra-
sound guidance and 80  % using anatomical landmarks 
(p =  0.002; odds ratio =  13.5, 95  % CI 1.7–108.7). The 
success rate at the first attempt was clearly higher with 
ultrasound guidance (85.5 versus 54.5  %, p  =  0.000). 
The rate of complications decreased from 18.2 to 5.5  % 
(p = 0.039) with ultrasound guidance. This study there-
fore shows that ultrasound guidance of femoral dialysis 
catheter placement reduces the failure rate, the number 
of attempts at femoral venous puncture and the inci-
dence of complications related to catheter placement, in 
accordance with all data and recommendations concern-
ing the placement of central venous catheters. However, 
the paucity of data and the small patient numbers pre-
vent a strong recommendation.
2.1.11 Catheters for RRT should be removed as soon as 
they are no longer necessary. (Expert opinion) 
Strong agreement
Temporary dialysis catheters should be considered as 
a central venous line at risk of infection and mechanical 
complications and a potential source of increased mor-
bidity and mortality. Their usefulness should therefore be 
reassessed daily and they should be removed once RRT is 
no longer necessary.
2.1.12 An arteriovenous fistula should not be used in 
the absence of relevant expertise. (Expert opin-
ion) Strong agreement
An arteriovenous fistula is an anastomosis between an 
artery and a superficial vein, generally situated on the 
forearm or inner face of the arm, which gives reliable 
and functional vascular access for dialysis of patients in 
chronic renal failure. Given the potential complications 
associated with repeated puncture of the arteriovenous 
fistula (skin damage, recirculation, aneurysm, local or 
systemic infection, thrombosis and hematoma), eve-
rything should be done to preserve this vascular access 
[59]. Thus, the puncture of an arteriovenous fistula by a 
physician or nurse calls for particular expertise. If this 
expertise is lacking, the vascular access for RRT requires 
the placement of a double-lumen catheter in the internal 
jugular vein or femoral vein.
Area 2.2: Membranes
2.2.1 Unmodified cellulose membranes (Cuprophan) 
should probably not be used for the management 
of patients with acute renal failure. Strong agree-
ment
The biocompatibility of dialysis membranes is generally 
defined by their capacity to activate mediators of inflam-
mation (essentially the alternative complement pathway) 
and granulocytes, in  vitro. However, in clinical use, the 
activation of inflammation at the membrane does not 
only depend on the membrane characteristics, but also 
on anticoagulation and on the quality of the dialysis (or 
replacement) fluid. Biocompatibility therefore depends 
on the whole dialysis system (type of membrane, antico-
agulation, fluid used). Randomized studies of the survival 
of acute renal failure patients in intensive care accord-
ing to the type of membrane used [60–75] do not yield 
a definitive conclusion because of the small total number 
of patients studied (under 650). However, meta-analyses 
suggest excess mortality with Cuprophan membranes, 
at the limit of significance. It therefore seems prudent to 
avoid the use of Cuprophan membranes in intensive care. 
In contrast, the use of cellulose acetate membranes does 
not seem to be associated with a risk of excess mortality. 
There is no trend to superiority of a given type of syn-
thetic membrane over another.
2.2.2 Use should be made of membranes of high 
hydraulic permeability (high ultrafiltration coeffi-
cient) for convective dialysis techniques (hemofil-
tration). (Expert opinion) Strong agreement
2.2.3 In intermittent hemodialysis, membranes of high 
hydraulic permeability should not be used in the 
absence of ultrapure dialysate. (Expert opinion) 
Strong agreement
The hydraulic permeability of a membrane is defined 
by an ultrafiltration coefficient (in mL/h/mmHg/m2 of 
membrane area). This permeability is proportional to the 
number of pores per unit area and to the mean radius 
of the pores to the power 4. Convective dialysis tech-
niques (hemofiltration) require a high hydraulic perme-
ability (≥20  mL/mmHg/m2/h), to permit a sufficient 
ultrafiltration flow rate without excessive pressure. Dif-
fusive methods (hemodialysis) are, on the other hand, 
perfectly compatible with a low ultrafiltration coefficient 
(<5  mL/mmHg/m2/h). The use of a membrane of high 
ultrafiltration coefficient in hemodialysis can generate 
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filtration-backfiltration movements during treatment 
which may provoke the passage of endotoxin or micro-
bial debris.
2.2.4 It does not seem useful to use a membrane of high 
porosity (high cutoff) or of high adsorption capac-
ity for the treatment of septic shock. (Expert opin-
ion) Strong agreement
One of the characteristics of an RRT membrane is 
its permeability limit or cutoff. Below the cutoff, in 
hemofiltration, each molecule has a sieving coefficient, 
defined by the ratio of [concentration of the molecule in 
the ultrafiltrate]/[concentration of the molecule in the 
plasma]. This ratio is 1 for small molecules and gener-
ally <0.1 for molecules of molecular weight above 15 kDa. 
Membranes with a high hydraulic permeability also gen-
erally have a high permeability to medium-sized mol-
ecules (porosity). There is no evidence of a significant 
difference in survival rate with membranes of high per-
meability or high porosity in acute renal failure patients. 
The same is true of so-called superpermeable membranes 
or membranes of very high porosity, with in vitro cutoffs 
of 60–100 kDa (≤60 kDa in vivo). These membranes were 
created to improve removal of medium-sized molecules, 
immunoglobulin light chains and cytokines, at the cost, 
however, of more or less large loss of albumin. There is no 
comparative study of mortality in intensive care patients 
with these superpermeable membranes. The studies are 
preliminary and the value of removing cytokines in sep-
tic shock is not established. Likewise, there is no study 
comparing the survival of patients according to the 
adsorption capacity of the membranes used. No specific 
membrane can, therefore, be recommended in the man-
agement of septic shock patients.
2.2.5 Heparin-coated or heparin-binding membranes 
should probably not be used to reduce anticoagu-
lation of the RRT circuit. Strong agreement
Certain specifically treated membranes bind 5 times more 
heparin on rinsing than other membranes. Others are coated 
with heparin. The value of these membranes in RRT in inten-
sive care patients has not been demonstrated. Studies of their 
use to avoid systemic anticoagulation are contradictory and 
so no definitive conclusion can be drawn [76–79].
Area 2.3: Anticoagulation
2.3.1 In patients at high risk of hemorrhage or present-
ing coagulopathy:
2.3.1.1 In intermittent RRT, systemic anticoagu-
lation should probably be avoided. Poor 
agreement
2.3.1.2 In continuous RRT, regional citrate anti-
coagulation should probably be preferred 
to no anticoagulation, unless there is a 
contraindication. Strong agreement
2.3.1.3 In continuous RRT, no anticoagulation 
should probably be preferred if there is a 
contraindication to citrate. (Expert opin-
ion) Poor agreement
In patients at high risk of hemorrhage, the use of sys-
temic anticoagulation is not recommended when RRT is 
indicated, as the expected advantage regarding the circuit 
is outweighed by the risk of bleeding.
The use of regional citrate anticoagulation seems to be 
the method of choice in these situations. In intermittent 
hemodialysis, however, the lack of a secure administra-
tion procedure makes its use complex.
In continuous dialysis, the strictly regional nature 
(only the circuit) of citrate anticoagulation means that it 
is preferred for first-line use. Three observational stud-
ies [80–82] in patients at high risk of hemorrhage have 
reported a significant decrease in hemorrhagic com-
plications with citrate use. For ethical reasons, no ran-
domized trial has compared citrate with heparin when 
there is a high risk of hemorrhage. However, most pro-
spective randomized studies [83–87] have shown a sig-
nificant reduction in hemorrhagic complications in the 
citrate group, despite the low risk of hemorrhage of the 
study populations.
When citrate is contraindicated, no anticoagulation 
should be preferred to systemic heparin anticoagulation. 
However, nonuse of anticoagulation in RRT exposes the 
patient to high consumption of coagulation factors. No 
study has demonstrated the value of circuit adjustments 
designed to limit thrombosis, such as the use of a high 
predilution dose or periodic rinsing.
Regional heparin-protamine anticoagulation is not rec-
ommended, irrespective of the method of dialysis (contin-
uous or intermittent). It exposes patients to the side effects 
of both heparin (notably the risk of heparin-induced 
thrombocytopenia) and protamine (principally anaphy-
laxis, platelet dysfunction, hypotension, and pulmonary 
vasoconstriction with a risk of right ventricular failure) 
[88]. As heparin has a much longer half-life than prota-
mine, this technique is difficult to titrate and also exposes 
patients to a rebound effect upon withdrawal of treatment.
2.3.1.4 In children, continuous RRT can be done 
without anticoagulation or by using 
regional citrate anticoagulation, the 
choice being guided by the experience of 
the team. (Expert opinion) Strong agree-
ment
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The use of citrate in dialysis in children offers an inter-
esting alternative to heparin, notably for patients at high 
risk of hemorrhage. Few pediatric studies have been con-
ducted and none is sufficiently relevant to conclude that 
citrate is superior to heparin. The recommendations for-
mulated are thus those of experts.
Bunchman et  al. reported filter lifetimes of approxi-
mately 72 h on average, in a series of 14 patients on con-
tinuous venovenous hemofiltration with dialysis [89] and 
in another series of 9 patients on continuous venovenous 
hemofiltration [90], without hemorrhagic complications. 
In a study of 9 patients, Elhanan et al. reported filter sur-
vival of up to 5 days [91].
In comparison with heparin, the observational study of 
Brophy et al. [92] in a cohort of 138 patients (93 heparin, 
37 citrate, 9 no anticoagulation) showed increased hemor-
rhagic complications with heparin, an identical filter lifes-
pan (heparin versus citrate) and increased filter lifespan 
(citrate anticoagulation/heparin versus no anticoagulation).
As for toxicity/risk of citrate accumulation, Chadha 
et  al. [93] showed, in a series of 5 patients undergo-
ing continuous venovenous hemofiltration, satisfactory 
clearance of calcium-citrate complexes. The risks in 
terms of biochemical values (metabolic acidosis or alka-
losis, hypocalcemia) should be known and closely moni-
tored using point-of-care testing. Concentrated citrate 
increases the risk of citrate toxicity [93], whereas lower 
concentrations may increase effluent flow rate to above 
recommended values [94]. These risks must be taken into 
account when choosing the concentration of citrate solu-
tion, which varies between suppliers, whence the need 
for specialist medical expertise.
Lastly, an observational study of 344 patients [95], 57 % 
of whom were treated with citrate, shows that the tech-
nique is widely used by North American teams and prob-
ably underused by European teams.
These observational studies of small populations do not 
enable a recommendation to be made with a sufficient level of 
proof. The use of citrate by pediatric teams calls for great mas-
tery of the prescription and of the biochemical monitoring.
2.3.2  In patients at low risk of hemorrhage not requir-
ing systemic anticoagulation:
2.3.2.1 In intermittent RRT, unfractionated 
heparin or low-molecular-weight hepa-
rin should probably be preferred to other 
systemic anticoagulants. (Expert opin-
ion) Strong agreement
2.3.2.2 In continuous RRT, in adults, regional 
citrate anticoagulation should probably 
be preferred, unless there is a contrain-
dication, so as to prolong circuit lifetime. 
Poor agreement
2.3.2.3 In continuous RRT, if there is a contrain-
dication to citrate, unfractionated heparin 
anticoagulation should probably be pre-
ferred. (Expert opinion) Strong agreement
In intermittent dialysis, a meta-analysis of 11 randomized 
studies in patients with end-stage renal failure found no dif-
ference between unfractionated heparin and low-molec-
ular-weight heparin in terms of bleeding complications 
or antithrombotic efficacy [96]. If low-molecular-weight 
heparin is chosen, its dosage should be adapted (elimination 
principally renal) to prevent a risk of accumulation and the 
occurrence of hemorrhagic complications. The dose used in 
intermittent dialysis is below that used in therapeutic antico-
agulation, notably in scheduling the injections because of the 
long half-life of low-molecular-weight heparin. Regular anti-
Xa activity assay seems desirable when use is prolonged.
In continuous dialysis, regional citrate anticoagula-
tion significantly extends circuit lifetime compared with 
heparin. This recommendation is based on the results of 
6 randomized studies and 8 observational studies that 
compared regional citrate anticoagulation with heparin 
anticoagulation in patients requiring continuous RRT 
[80, 82–87, 92, 97–103]. Regional citrate anticoagulation 
also limits hemorrhagic complications [80–87, 98–100, 
102, 103], economizes use of blood [80, 82, 83, 85–87, 
101] and limits consumption of platelets [87, 98–100, 
102], without altering mortality [80, 87, 97, 98, 100, 104].
If citrate anticoagulation is contraindicated or unavail-
able, unfractionated heparin (partial thromboplastin time 
target 1.5 times the control) was preferred by the experts 
because of its pharmacokinetics and its reversibility com-
pared with low-molecular-weight heparin.
2.3.2.4 In children, in continuous RRT, citrate or 
unfractionated heparin should be used for 
anticoagulation, the choice being guided by 
the experience of the team. Strong agree-
ment
Cf argument of recommendation 2.3.1.4
2.3.3 In patients requiring systemic anticoagulation:
2.3.3.1  Systemic anticoagulation using heparin 
should probably be preferred to other 
anticoagulants. (Expert opinion) Strong 
agreement
2.3.3.2  In patients with suspected or proven hep-
arin-induced thrombocytopenia, in addi-
tion to cessation of heparin treatment, it is 
possible to use regional citrate anticoagu-
lation as a complement to the anticoagula-
tion of heparin-induced thrombocytope-
nia. (Expert opinion) Strong agreement
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If there is repeated thrombosis during effective heparin 
anticoagulation, despite the usual precautions (sufficient 
blood flow, filtration fraction <20 %, no catheter dysfunc-
tion), heparin-induced thrombocytopenia should be sus-
pected and tested for. Regional citrate anticoagulation is 
certainly the best option.
Area 2.4: Reverse osmosis water
2.4.1 A quality program should be set up to ensure that 
the reverse osmosis water meets regulatory stand-
ards. (Expert opinion) Strong agreement
The quality of the water used for intermittent RRT 
techniques in intensive care should comply with the cir-
culars and standards defined in the European pharma-
copeia in force for chronic hemodialysis. Regular checks 
of management of water quality are the responsibility of 
the pharmacist in association with the intensivist. Water 
quality control should be guaranteed permanently by 
setting up a suitable and effective quality assurance 
system by following the circulars (DGS/DH/AFSSAPS 
2000-337, GGS/DH/AFSSAPS 2007-52) and standards 
(NF S93-310:2004 and NF S93-315: 2008) in force.
Area 3: Practical aspects
Area 3.1: Choice of the method
3.1.1 Continuous and intermittent RRT techniques can 
be used equally, taking into account their availabil-
ity and the experience of the team. Strong agree-
ment
3.1.2 Diffusive and convective RRT techniques can be 
used equally, taking into account their availability 
and the experience of the team. Strong agreement
Several randomized studies and meta-analyses have 
examined the safety and outcome of patients treated by 
intermittent hemodialysis and hemofiltration [105–114]. 
Their data suggest that none of these techniques has an 
advantage over the others in terms of survival. Several 
of these studies included hemodynamically unstable 
patients [108, 109, 111, 113], and one study excluded 
them [107]. The rate of hemodynamic instability either 
did not differ significantly [106, 108, 113] or was not in 
favor of intermittent hemodialysis [105, 112]. Most stud-
ies, however, provide limited information on these crite-
ria, and it was only a secondary criterion in most studies. 
The dialysis modalities, prescribed doses of dialysis, time 
before initiation and criteria of hemodynamic instability 
varied greatly between the studies, making their compar-
ison difficult.
The data on the recovery of renal function after RRT 
are discordant [115, 116]. Observational studies suggest 
an increased risk of persistent renal failure in patients 
initially treated by intermittent hemodialysis, whereas 
data from randomized studies indicate no difference 
according to technique [107–109, 111, 112, 116]. A 
recent meta-analysis indicated an increased risk of inter-
mittent techniques [116]. The discordance between the 
data from observational studies (odds ratio 1.99; 95 % CI 
1.53–2.59) and from randomized studies (odds ratio 1.15; 
95 % CI 0.78–1.68) prevents the drawing of any definitive 
conclusion.
The speed of correction of metabolic anomalies is 
greater with intermittent hemodialysis, but the advantage 
of intermittent hemodialysis over continuous techniques 
has not been specifically assessed. There are no literature 
data indicating a superiority or inferiority of diffusive 
versus convective modalities.
3.1.3 In patients with brain damage and a risk of intrac-
ranial hypertension, continuous or sustained low-
efficiency dialysis (SLED) should probably be pre-
ferred. (Expert opinion) Strong agreement
Intermittent techniques, unlike continuous techniques, 
can induce osmotic variations [117], which lead to cer-
ebral edema (dialysis disequilibrium syndrome) [117, 
118]. A single observational study indicates that intracra-
nial pressure increases in cranial trauma patients during 
intermittent hemodialysis [119]. However, no study has 
compared the neurological morbidity of the two tech-
niques in patients with brain damage.
Area 3.2: Peritoneal dialysis
3.2.1 In children and neonates, peritoneal dialysis is 
possible, in particular postoperatively after heart 
surgery, with a view to salt and water depletion, 
because of its ease of use. Poor agreement
3.2.2 In children and neonates, peritoneal dialysis is 
possible for acute renal failure when there is no 
criterion for emergency dialysis. Poor agreement
Peritoneal dialysis (PD) is an RRT technique that is still 
much used in pediatric intensive care in both emerging 
countries and the industrialized world. The main indica-
tions reported in the literature are salt and water deple-
tion in the postoperative period after heart surgery and 
the treatment of isolated acute renal failure. Several 
studies confirm the efficacy of PD in these indications 
[120–130]. The time needed to achieve effective dialysis 
with PD means that it cannot be used when there is an 
emergency indication. The principal criterion for choos-
ing PD over another technique is that it does not require 
vascular access for children at risk of terminal chronic 
renal insufficiency. Three studies of low methodologi-
cal quality (nonrandomized) compared PD with another 
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RRT technique in a postoperative setting [131] or in dif-
ferent types of renal failure [132, 133]. Two of these stud-
ies [132, 133] found an identical mortality, while the third 
[134] showed excess mortality in a hemodialysis group, 
but this study suffered from bias in the distribution of the 
patients by disease severity. One study [132] found that 
caloric intake was greater in continuous arteriovenous 
hemofiltration and in continuous veno-venous hemofil-
tration than in PD. One study [132] showed an associa-
tion between use of PD and vasopressor treatment. In the 
indications cited above, it is not possible to conclude that 
one or other technique is superior to another. In all cases, 
the choice of a PD technique means that the care team 
must be completely familiar with the procedures, compli-
cations and monitoring.
3.2.3 In adults, peritoneal dialysis should probably not 
be used first-line. Strong agreement
There are few comparative studies for assessment of 
the role of PD in the management of acute renal failure 
requiring RRT in adults. The three studies available are 
contradictory regarding mortality [134–136]. In contrast, 
the time needed to achieve satisfactory metabolic control 
and adequate volume control means that PD is unsuited 
to life-threatening situations. While PD is useful in cer-
tain parts of the world where use of other techniques is 
difficult, it cannot be recommended when these other 
methods are available.
Area 3.3: Dialysis dose
3.3.1 In intermittent RRT the minimum delivered 
dose of dialysis should probably be (1) three 
sessions per week of at least 4  h with a blood 
flow >200 mL/min and a dialysate flow >500 mL/
min, or (2) a Kt/V index  >3.9 per week, or (3) 
maintenance of a predialysis urea concentration of 
20–25 mmol/L. Strong agreement
Three randomized studies evaluated the impact of 
the dialysis dose in intermittent RRT in intensive care 
patients [32, 137, 138]. The first two used the Kt/V index 
to measure and compare the doses of dialysis delivered 
[32, 138]. The single-center study of Shiffl et  al. com-
pared 3.5-h sessions delivered daily or every 2  days in 
160 patients [138]. The weekly Kt/V was 3.0 ± 0.6 in the 
conventional renal support group versus 5.8 ± 0.4 in the 
intensive dialysis group. The authors observed a signifi-
cant 18 % (95 % CI 33 %/4 %) reduction in mortality. Two 
biases can, however, explain the excess mortality in the 
conventional group: (1) the delivered dose of dialysis was 
particularly low, below that required in chronic dialysis 
patients, (2) the management of the water balance by 
short sessions every two days required ultrafiltration flow 
rates that were much higher and poorly tolerated. A sec-
ond, multicenter study performed in the USA by the VA/
NIH in 1124 patients compared two groups treated with 
4-h sessions three or six times a week [32]. The average 
daily Kt/V was 3.93 in the conventional group and 7.1 in 
the intensive dialysis group. On average, the plasma urea 
concentration before the sessions was 25 ± 12 mmol/L in 
the conventional group and 16 ± 9 mmol/L in the inten-
sive dialysis group. Mortality did not differ between the 
two groups (35.2 % conventional versus 38.2 % intensive). 
In the third study, prolonged daily sessions of low-effi-
ciency hemodialysis were used in 156 patients to main-
tain plasma urea at 20–25 mmol/L or <15 mmol/L [137]. 
The patients received 8 h of treatment/day on average for 
a mean urea concentration of 19.1 ± 6.8 mmol/L in the 
conventional group versus 18 h of treatment per day for 
a urea concentration of 11.4 ± 4.1 mmol/L in the inten-
sive dialysis group. Mortality at day 14 was 29  % in the 
two groups, which limited the power of this study, the 
expected mortality of which was 60  %. When consid-
ered in a meta-analysis, these studies do not show that a 
higher dialysis dose was superior in terms of mortality or 
dependence on chronic dialysis. It is not, however, pos-
sible to conclude that the dialysis dose has no impact on 
the prognosis of intensive care patients, but rather that 
there is a minimum dose, used in the control arm of these 
three studies, above which increase provides no further 
benefit. It is not, however, possible to define a single 
minimum dose because in these studies the dose and the 
delivery modalities (clearance, time, frequency) were not 
identical. Current data do not allow elimination of a pos-
sible impact of the delivered dose of dialysis on the prog-
nosis in certain subgroups of patients, such as those with 
acute renal failure of intermediate severity [139].
3.3.2 In continuous RRT, the minimum delivered dose 
of dialysis should probably be 20–25  mL/kg/h 
of effluent, by filtration and/or diffusion. Strong 
agreement
In continuous RRT, dialysis dose is the total volume 
of effluent, i.e., the sum of the ultrafiltration volume 
obtained by convection and the volume of dialysate 
obtained by diffusion. Single-center and old studies sug-
gest that an increase in dialysis dose in continuous RRT 
could increase patient survival. Ronco and colleagues 
reported greater survival of patients receiving 35  mL/
kg/h of filtration with reinjection postdilution in compar-
ison with patients receiving 25 mL/kg/h (57 versus 41 %, 
p 0.0007) [140]. Saudan and colleagues included 206 
patients in a randomized trial comparing hemofiltration 
with a total effluent flow rate of 25 mL/kg/h with hemo-
diafiltration where a 15 mL/kg/h dialysate flow rate was 
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added to ultrafiltration of 25 mL/kg/h, i.e., a total effluent 
flow rate of 35 mL/kg/h [141]. Survival at day 90 was sig-
nificantly higher in the hemodiafiltration group (59 ver-
sus 34 %, p = 0.0005).
Two larger randomized, multicenter studies were sub-
sequently designed to confirm or deny the advantages 
of using a high dialysis dose in continuous RRT. The 
first was a VA/NIH randomized study of 1124 intensive 
care patients with acute renal failure, 615 of whom were 
treated by predilution hemodiafiltration (with a ratio 
of dialysate to replacement fluid of 1:1) that was inten-
sive (35  mL/kg/h) or conventional (20  mL/kg/h) [142]. 
Mortality at day 60 was similar in the two groups. The 
patients receiving intensive treatment had more compli-
cations, essentially metabolic disorders. The second study 
was the Randomized Evaluation of Normal versus Aug-
mented Level (RENAL) Replacement Therapy Study, in 
which 1508 patients were treated by postdilution hemo-
diafiltration with a ratio of dialysate to replacement fluid 
of 1:1. The patients were randomized to intensive (40 mL/
kg/h) or conventional (25 mL/kg/h) treatment [143]. Sur-
vival at day 90 and recovery of renal function did not 
differ between the two groups. There were more compli-
cations in the patients in the intensive dialysis group. A 
meta-analysis of seven trials comparing a conventional 
dialysis dose with an intensive dose in continuous RRT 
found no difference in the prognosis of the patients (odds 
ratio 0.87, CI 0.71–1.06).
The VA/NIH and RENAL studies show that increasing 
the dose of continuous RRT to above 25 mL/kg/h of total 
effluent is of no benefit in intensive care patients treated 
for acute renal failure.
3.3.3 The delivered dose of dialysis should be adapted to 
the patient’s needs in terms of control of metabo-
lism, electrolyte balance and acid–base equilib-
rium. The onset of hypokalemia and/or hypophos-
phatemia must be prevented. The dosage of drugs 
removed by RRT should be adapted to the dose 
delivered. (Expert opinion) Strong agreement
In an intensive care patient, the dialysis dose should 
not be defined only by the quantity of urea removed. The 
aims of RRT are maintenance of water-electrolyte bal-
ance, acid–base equilibrium and nutritional balance. The 
heterogeneity of the patients included in randomized tri-
als and their selection using inclusion criteria prevents 
recommendation of a conventional dialysis dose adapted 
to all patients. In addition, the therapeutic aims of RRT 
have to be adjusted in light of the patient’s progress. An 
increase of the dialysis dose is required in certain clini-
cal circumstances, such as life-threatening hyperkalemia, 
severe metabolic acidosis (pH  <  7.20), and tumor lysis 
syndrome [144]. On prescription of a session of RRT, it 
should be borne in mind that the delivered dose of dial-
ysis is in general below the prescribed dose. The main 
technical factors that decrease the intensity of RRT are 
treatment interruption (alarms, moving of the patient), 
loss of membrane efficiency (clogging and coagulation) 
and dysfunction of the vascular access route.
Whatever the method, intensification of RRT fre-
quently generates metabolic disorders like hypokalemia 
and hypophosphatemia, with unfavorable clinical con-
sequences [32, 145, 146]. To prevent underdosage, dos-
ages of drugs, particularly anti-infective agents, should be 
adapted to the intensity of the RRT [147, 148].
3.3.4 In intermittent RRT, the length and/or frequency 
of sessions should probably be increased in cases 
of hypercatabolism and/or severe metabolic disor-
der and/or an indication for salt and water deple-
tion. (Expert opinion) Strong agreement
The heterogeneity and mild renal failure of patients 
included in studies comparing different intensities of 
dialysis delivered in intermittent RRT prevent determi-
nation of the minimum dose to be delivered to patients 
with more severe disease. It should be remembered that 
in the VA/NIH study the patients treated by intermittent 
RRT had no hemodynamic impairment [142]. In these 
patients, the urea production rate, the accumulation 
of fluid that increases the volume of distribution of the 
urea and the severity of the metabolic disorders probably 
necessitate a higher dialysis dose.
Increase in the length or frequency of the sessions 
depends on the clinical objective. It is clearly estab-
lished that an increase in session length from 4  h to 
6–8 h will raise the efficiency of removal of a solute with 
a high volume of distribution like urea [149]. Movement 
of intracellular urea towards the plasma by the gen-
eration of a diffusion gradient is time-dependent. The 
heterogeneity of tissue perfusion results in a mismatch 
between the stock of urea and the perfusion rate. Fre-
quent, short high-efficiency dialysis sessions (high flow 
of blood and dialysate) effectively remove solute with 
a low volume of distribution, i.e., distributed mainly 
in plasma [150]. Lastly, if the aim of RRT is to control 
sodium and water balance by depletion, the use of daily 
sessions seems more effective and better tolerated. In 
the VA/NIH study, the use of sessions 6  days/7 versus 
3  days/7 resulted in a blood volume depletion above 
2–3 L/week [32]. In certain studies, it was observed that 
control of sodium and water balance was facilitated by 
continuous RRT [151, 152]. This suggests that intermit-
tent techniques should be used daily when large deple-
tion is indicated.
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3.3.5 In continuous RRT, the dialysis dose should not be 
increased for sepsis alone. Strong agreement
Pro- and anti-inflammatory mediators were found in 
the ultrafiltrate of patients with sepsis treated by continu-
ous hemofiltration [153]. Based on the assumption that 
hemofiltration nonspecifically reduces the concentration 
peaks of these mediators and thus has an immunomodu-
latory effect, this technique was soon put forward as an 
adjuvant treatment of septic shock. Animal studies gave 
encouraging results, with a decrease in catecholamine 
doses in animals treated by high-volume hemofiltration 
(>50  mL/kg/h). The first clinical experience in human 
subjects was reported by Honoré and colleagues in 20 
patients with refractory septic shock. Using a very big 
ultrafiltration dose (6 L/h) for 4 h followed by a conven-
tional dose [154], they noted improved hemodynamics, 
metabolic equilibrium, and survival at day 28 (compared 
with predicted mortality), when high-volume hemofiltra-
tion was initiated early. Several authors have unsuccess-
fully attempted to show that high-volume hemofiltration 
confers improved survival in septic shock [155–157]. 
Finally, Borthwick and colleagues [158] attempted to per-
form a meta-analysis of the use of high-volume hemo-
filtration in sepsis using only three randomized studies 
including a total of 64 patients. Because of the hetero-
geneity of these three studies, their endpoints, and their 
small populations, the analysis proved impossible.
Various prospective randomized studies assessing the 
effect of higher doses of dialysis on mortality have also 
failed to find a significant effect, even by analysis in the 
subgroup of patients with septic shock [140, 142, 149–
152]. In a meta-analysis of 9 randomized trials compar-
ing two intensities of dialysis in 1786 patients, a specific 
analysis was done to assess the impact of dialysis dose in 
the subgroup of septic shock patients. Intensification of 
the dialysis dose was not associated with reduced mortal-
ity (odds ratio 1.02, CI 95 % 0.85–1.23).
Adverse effects associated with the use of high-flow 
ultrafiltration could counterbalance the modulating 
effect of this treatment. High-volume hemofiltration 
may lead to major metabolic disorders (in particular, 
hypophosphatemia and hypokalemia), deep hypother-
mia, increased clearance of drugs (particularly antibiot-
ics), and deficiency in micronutrients such as selenium.
Currently available data therefore suggest that sepsis in 
a patient with renal failure does indicate increase of dial-
ysis dose.
Area 3.4: Adjustments
3.4.1 It does not seem necessary to use heparin when 
rinsing RRT circuits. (Expert opinion) Poor agree-
ment
Although there is no corresponding study, it is gen-
erally agreed that the circuit should be rinsed with iso-
tonic saline solution and that arterial and venous lines 
should be connected simultaneously to avoid volume 
depletion induced by rinsing. Heparinization of the 
rinsing fluid is debated because no study has tested its 
usefulness. In hemodialysis, it is not necessary to add 
heparin when rinsing the circuit. In hemofiltration, 
usual practice is to use 5000 IU of heparin in the second 
liter of fluid when rinsing the circuit so as to extend fil-
ter lifespan and increase adsorption capacity (no study). 
This approach, however, has not been validated by sci-
entific evaluation.
3.4.2 Nutritional intake of RRT patients should not be 
reduced. (Expert opinion) Strong agreement
3.4.3  In hemofiltration post-dilution, blood flow should 
be adjusted to keep the filtration fraction below 
25 %. (Expert opinion) Strong agreement
The estimated minimum blood flow is 150  mL/min. 
The filtration fraction should be kept below 25  % when 
there is unfractionated heparin anticoagulation (no study 
available). However, the best indicator of viscosity within 
the filter is the hematocrit, which should remain below 
40  % (no study available). Measurement of the hemato-
crit in the filter enables much better determination of the 
appropriate filtration fraction, particularly when predilu-
tion is used. The filtration fraction should be corrected 
according to the amount of predilution used. Routine 
use of the hematocrit in the filter obviates the need for 
these tedious calculations. The use of citrate, currently 
based on more effective anticoagulation, optimizes ther-
apy  while tolerating higher (up to 27  %) filtration frac-
tions (no studies available).
3.4.4 In intermittent hemodialysis of duration  <6  h, 
the blood flow rate in dialysis should be between 
200 and 300  mL/min and the dialysate flow 
rate  ≥500  mL/min for most patients. (Expert 
opinion) Strong agreement
3.4.5  In children, in intermittent hemodialysis of dura-
tion <6 h, the blood flow rate should start at 3 mL/
kg/min and increase to 5 mL/kg/min for the fol-
lowing sessions, and the dialysate flow rate should 
be at least 300 mL/min up to twice the blood flow 
rate in mL/min. (Expert opinion) Strong agree-
ment
Recommendations concerning session length and 
flow rates in intermittent hemodialysis are based on two 
main objectives: (1) delivery of the dialysis dose recom-
mended, (2) satisfactory hemodynamic tolerance. The 
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recommendations are therefore principally based on 
arguments related to the dose of dialysis (see recommen-
dation 3.3.1). So these recommendations apply to most 
patients. In certain clinical situations, it may be necessary 
to make adjustments essentially to prevent dialysis dis-
equilibrium syndrome, which may occur on initiation of 
RRT in patients with a high urea concentration. The aim 
is to avoid large variations in osmolality so as to prevent 
cerebral edema. There are no clearly defined settings in 
this situation, but a sharp drop in plasma urea concen-
tration should be avoided. The length of the session and 
the blood flow, and even the dialysate flow rate, should 
therefore be reduced. Note that use of a sodium-enriched 
dialysate, as recommended when there is hemodynamic 
instability (see recommendation 3.4.8), probably prevents 
this risk.
3.4.6 In sustained low-efficiency dialysis, low blood and 
dialysate flow rates should be used. (Expert opin-
ion) Strong agreement
Intermittent sustained low-efficiency hemodialysis 
(SLED) has been proposed as a hybrid of intermittent 
short-term high-efficiency hemodialysis and continu-
ous low-efficiency methods. Using a classic hemodialysis 
machine for a duration of 8–12 h, SLED enables slower 
dialysis and management of sodium and water balance 
over a longer period, while remaining intermittent. The 
expected effects are improved hemodynamic tolerance, 
reduced risk of dialysis disequilibrium syndrome, and 
increased dose delivered by plasma  refilling (equilibra-
tion of urea concentrations between plasma and inter-
stitial tissue), which is made possible by the prolonged 
session. This modality has been little evaluated and 
numerous protocols have been proposed, all based on 
a decrease in blood and dialysate flow rates, without it 
being possible to infer recommendations for clinical 
practice [159–161].
3.4.7 The arterial and venous lines should be connected 
simultaneously to avoid volume depletion. (Expert 
opinion) Strong agreement
3.4.8 In intermittent hemodialysis, lowering of dialysate 
temperature should probably be recommended, to 
improve hemodynamic tolerance. Strong agree-
ment
3.4.9 In intermittent hemodialysis, sodium concentra-
tion in the dialysate (conductivity) should prob-
ably be increased to  >145  mmol/L, to improve 
hemodynamic tolerance or when the urea concen-
tration is very high. Strong agreement
3.4.10 In intermittent hemodialysis, a bicarbonate buffer 
should probably be used. Strong agreement
Recommendations 3.4.6–3.4.10 concern the conditions 
recommended for optimization of hemodynamic toler-
ance in intermittent hemodialysis. This is important as 
intradialytic hypotension during intermittent hemodialy-
sis sessions can generate ischemia–reperfusion episodes, 
which maintain or worsen tubular necrosis. The influence 
of thermal balance, dialysate composition, and sodium 
and water balance has been demonstrated above all in 
chronic dialysis, in improving tolerance of blood pres-
sure changes in frail patients. Use of a moderately cooled 
dialysate limits warming induced by RRT which is accom-
panied by a decrease in vasomotor tone [162]. For the 
dialysate, the choice of buffer and the sodium conductiv-
ity are important. Acetate buffer, which induces vasople-
gia and contractile dysfunction [163], has been replaced 
by bicarbonate. High sodium conductivity results in 
increased plasma sodium and so limits the rapid drop in 
osmolality, notably at the start of the session. This helps 
improve hemodynamic tolerance [164]. Few studies have 
investigated the influence of these guidelines in intensive 
care patients undergoing dialysis because of acute renal 
failure. One study in intensive care that assessed the 
effect of these guidelines (bicarbonate buffer, dialysate 
enriched in sodium and moderately cooled, isovolemic 
connection and rational ultrafiltration) showed a clear 
improvement in hemodynamic tolerance [165]. Appli-
cation of these guidelines in a prospective randomized 
study showed that hemodynamic tolerance of the result-
ing intermittent hemodialysis was comparable with that 
of continuous RRT, which is reputed to be less likely to 
result in hemodynamic instability [108].
Area 4: Safety
Area 4.1: Procedures, training
4.1.1 RRT should be set up using an in-house procedure 
including at least specific prescription and moni-
toring, description of the technical procedures 
and required hygiene precautions and disinfection 
of monitors/hemodialysis machines. (Expert opin-
ion) Strong agreement
4.1.2 The medical and paramedical teams should be 
trained in accord with professional standards, 
so they acquire the required skills in using RRT 
monitors/hemodialysis machines, in the preven-
tion and treatment of complications of the dif-
ferent techniques and in the traceability of events 
and hygiene procedures. (Expert opinion) Strong 
agreement
RRT is a highly technical procedure involving a chain 
of interventions subject to the risk of human error and/or 
equipment failure. In 2008 the SRLF and the SFAR drew 
up recommendations to ensure the safety of RRT [166].
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RRT requires complex equipment and precise settings. 
Nurses play the main role in RRT [167]. When the tech-
nique used is hemodialysis, adjustments have a direct 
impact on tolerance and the use of good practice proce-
dures significantly reduces complications [165, 168, 169]. 
Although little evaluated, there are many arguments in 
favor of management of RRT techniques based on stand-
ard procedures and for a training program specific to 
these techniques.
Definition of healthcare procedures is a recognized 
way of improving intensive care practices [170, 171]. 
Understanding of the content and aims of these proce-
dures is, however, essential if they are to be applied cor-
rectly. Expert recommendations and experience indicate 
that management of RRT sessions by trained personnel 
using standardized procedures is necessary [167, 168, 
172–176]. In a recent survey of renal failure manage-
ment in 188 intensive care departments in the United 
Kingdom, 73  % of the departments reported that they 
had a standardized procedure for RRT [177]. There are 
numerous infectious risks associated with RRT. The 
French Society for Hospital Hygiene has drawn up rec-
ommendations stipulating that good hygiene practices 
in performing RRT must be applied in accordance with 
specific procedures established by the healthcare teams 
and approved by the institution and that the personnel 
must be trained in these procedures [178]. In addition to 
standard precautions for the prevention of bacterial and 
viral transmission, management of the disinfection of the 
hemodialysis machine should also be included [178].
Training of intensive care personnel in RRT is made 
difficult by the low frequency of use of this technique. A 
study carried out between 1997 and 2007 in 108 intensive 
care units in France and the USA showed that one quar-
ter of the units treated fewer than 10 patients/year [179]. 
Frequent staff turnover, the predominance of young qual-
ified nurses and the technique-dependent specificity of 
the equipment used are additional hindrances to acquisi-
tion of the required skills [168]. Healthcare teams should 
ideally have access to structured training in RRT, with 
assessment of learning.
4.2 Dialysis catheter management
4.2.1 Use of a dialysis catheter should be reserved for 
RRT. (Expert opinion) Strong agreement
Because of its specificity (diameter, length, locking 
solution) and indication for placement (use of RRT), the 
dialysis catheter in intensive care should not be used for 
purposes other than RRT, so as to minimize the risk of 
complications associated with dialysis catheters: throm-
bosis, dysfunction, and infection.
4.2.2 RRT catheters should be handled according to the 
recommendations applicable to central venous 
catheters. (Expert opinion) Strong agreement
Most data on management of temporary dialysis cath-
eters come from studies on indwelling dialysis catheters 
in patients with end-stage renal failure or from studies 
on central venous catheters in intensive care. Although 
the profile of intensive care patients differs from that of 
chronic renal failure patients, and although dialysis cath-
eters are different from central venous catheters in terms 
of handling, management, and complications (dysfunc-
tion, thrombosis, infection), the data suggest that dialysis 
catheters should be handled according to the recommen-
dations applicable to central venous catheters [34, 37, 38, 
180]
4.2.3 Failure to attain or maintain a blood flow rate nec-
essary and sufficient to deliver an adequate dose of 
treatment should probably be considered as a cri-
terion of RRT catheter dysfunction. (Expert opin-
ion) Strong agreement
There is no consensual definition of dialysis cath-
eter dysfunction in intensive care patients. In patients 
undergoing chronic hemodialysis, catheter dysfunc-
tion is conventionally defined using hemodynamic cri-
teria. In intensive care, catheter dysfunction should be 
considered when it is impossible to aspirate the blood 
in at least one of the lines or to deliver a catheter blood 
flow rate  >150  mL/min [181]. Dysfunction can also be 
defined by the inability to administer the prescribed dial-
ysis dose despite lowering prepump arterial pressure to 
−250  mmHg or raising venous pressure to 250  mmHg 
[43].
4.2.4 Hypovolemia should be eliminated when there 
is catheter dysfunction. (Expert opinion) Strong 
agreement
4.2.5 Thrombosis should be eliminated when there is 
catheter dysfunction unrelated to hypovolemia. 
(Expert opinion) Strong agreement
Catheter dysfunction generally occurs early (<10 days) 
[43, 181] and is therefore associated with position-
ing problems or blood flow below the rate required for 
RRT. There is a greater risk of femoral catheter dysfunc-
tion if its distal end does not reach the inferior vena cava 
[43]. Likewise, there is a greater risk of internal jugular 
catheter dysfunction if its distal end does not reach the 
right atrium [182]. Late-occurring catheter dysfunction 
is principally related to catheter thrombosis, partial or 
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complete obstruction of the catheter, or thrombosis out-
side the catheter in the cannulated vein [183].
4.2.6 In intermittent hemodialysis in adults, the RRT 
catheter should be changed as soon as possible 
if the lines have to be swapped, in the absence 
of hypovolemia. (Expert opinion) Strong agree-
ment
If the lines are swapped, recirculation may reduce the 
RRT dose administered during techniques that use high 
blood flow. If the aim is to deliver an adapted dose, only 
a change of catheter is indicated, once blood volume is 
restored.
4.2.7 It is not possible to recommend one type of lock-
ing solution rather than another (saline, heparin, 
citrate). (Expert opinion) Poor agreement
RRT catheter dysfunction is a frequent event that can 
lead to premature catheter replacement. Data on the influ-
ence of the locking solution (heparin, NaCl, citrate, etha-
nol) on dysfunction are scarce and essentially concern 
end-stage renal failure patients or venous access at the jug-
ular site [184–186]. Data from the study group Cathedia 
show no difference in catheter dysfunction between the 
jugular and femoral sites [43], a conclusion backed up by a 
recent small, single-center, randomized, open study of the 
effect of citrate locking solution on these 2 sites commonly 
used in intensive care (similar proportion in the 2 groups) 
[187]. The result of the principal outcome was in favor of 
the use of the citrate locking solution. There is also a “sig-
nal” concerning catheter infections, which did not differ in 
number between the two groups, but for which the time to 
onset was longer in the citrate locking solution group. This 
result could be due to bacteriostatic effects of the citrate, 
the role of which in these infections has yet to be investi-
gated in a study of suitable size. Nonetheless, heparin lock-
ing solutions are also widely used around the world, and a 
large-scale comparison of citrate locking solution, heparin 
locking solution, and saline locking solution is essential if 
the value of citrate locking solution is to be assessed in a 
cost-benefit analysis.
4.3 Extracorporeal circuit set‑up
 4.3.1 Connecting the circuit: 
 4.3.1.1 Before connecting the circuit, the patency 
of the vascular access should be checked. 
(Expert opinion) Strong agreement
 4.3.1.2 Two people are needed to set up the cath-
eter lines. (Expert opinion) Strong agree-
ment
 4.3.1.3 Optimal rinsing of the extracorporeal cir-
cuit is needed to minimize the amount of 
air, so as to reduce the risk of coagulation 
and of gas microembolism. (Expert opin-
ion) Strong agreement
 4.3.1.4 Connections between the vascular access 
and the extracorporeal circuit should be 
kept visible during dialysis to reduce the 
risk of inadvertent disconnection. (Expert 
opinion) Strong agreement
 4.3.1.5 Patient agitation should be prevented to 
avoid inadvertent disconnection. (Expert 
opinion) Strong agreement
 4.3.1.6 Blood flow in the extracorporeal cir-
cuit should be increased progressively to 
check that the vascular access is patent 
and the circuit airtight. (Expert opinion) 
Strong agreement
 4.3.1.7 In hemofiltration, convection should 
be started when the target blood flow is 
attained, so as to avoid excess hemocon-
centration in the filter. (Expert opinion) 
Strong agreement
4.3.2  During the session
4.3.2.1 Circuit pressures (arterial, venous, trans-
membrane) and pressure drop should 
be monitored closely. (Expert opinion) 
Strong agreement
4.3.2.2 The lines of the extracorporeal circuit 
should be fastened to avoid kinking and 
resultant stoppage of the blood pump. 
(Expert opinion) Strong agreement
4.3.2.3 The blood pump flow rate should be 
reduced and convection interrupted 
when moving the patient. (Expert opin-
ion) Poor agreement
4.3.2.4 Aseptic technique should be followed and 
introduction of air avoided when sam-
pling blood in the extracorporeal circuit. 
(Expert opinion) Strong agreement
4.3.2.5 The blood level in the bubble trap should 
be kept high to reduce the incidence of 
gas microembolism. (Expert opinion) 
Strong agreement
4.3.3  Disconnecting the circuit
4.3.3.1 Saline should be used to return blood in 
the extracorporeal circuit to the patient. 
(Expert opinion) Strong agreement
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4.3.3.2 On disconnection, the patient should be 
placed in the supine position to reduce 
the risk of gas embolism. (Expert opinion) 
Poor agreement
4.3.3.3 In infants weighing under 15  kg, the 
return blood flow should probably be less 
than or equal to 2  mL/kg/min. (Expert 
opinion) Poor agreement
These recommendations concerning practical manage-
ment of RRT sessions are all expert opinions based on 
the rules of good practice. No scientific publication has 
evaluated their impact. However, it seemed necessary 
for clinical practice to provide inexperienced teams with 
solid guidance on how to improve the implementation of 
these techniques.
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